Merck Serono sells women's health division to Teva
This article was originally published in Scrip
Executive Summary
Merck Serono has moved further towards focusing its pharmaceutical operations on neurodegenerative diseases, oncology, fertility, rheumatology and endocrinology by selling its women's health division Theramex to Teva Pharmaceutical Industries for €265 million.